← Back to Search

B.D Accucath 5.71 cm 20 Gauge ultralong intravenous catheter for Peripheral Intravenous Catheter Phlebitis

N/A

Waitlist Available

Led By Amit Bahl, MD.

Research Sponsored by William Beaumont Hospitals

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up study period, a maximum of 1 year

Awards & highlights

Study Summary

This trial is testing whether a new type of IV catheter is just as good as the old one.

Eligible Conditions

Peripheral Intravenous Vein Catheter Phlebitis
Intravenous Infection

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ study period, a maximum of 1 year

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~study period, a maximum of 1 year

This trial's timeline: 3 weeks for screening, Varies for treatment, and study period, a maximum of 1 year for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Catheter survival

Secondary outcome measures

Catheter-associated bloodstream infection

Catheter-associated thrombosis

First-stick success.

+3 more

Other outcome measures

Inflammatory complications by clinical assessment

Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: Experimental Arm B.D. Accucath 5.71 cm 20 Gauge catheterExperimental Treatment1 Intervention

Device BD 5.71 cm Accucath IV catheter with guidewire

Group II: Control Arm B.Braun 6.35 cm 20 Gauge catheterActive Control1 Intervention

Device 6.35 cm 20 Gauge B. Braun catheter without guidewire

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

William Beaumont HospitalsLead Sponsor

149 Previous Clinical Trials

112,858 Total Patients Enrolled

Amit Bahl, MD.Principal InvestigatorWilliam Beaumont Hospitals

Media Library

B.D Accucath 5.71 cm 20 Gauge ultralong intravenous catheter Clinical Trial Eligibility Overview. Trial Name: NCT04949854 — N/A

Peripheral Intravenous Catheter Phlebitis Research Study Groups: Control Arm B.Braun 6.35 cm 20 Gauge catheter, Experimental Arm B.D. Accucath 5.71 cm 20 Gauge catheter

Peripheral Intravenous Catheter Phlebitis Clinical Trial 2023: B.D Accucath 5.71 cm 20 Gauge ultralong intravenous catheter Highlights & Side Effects. Trial Name: NCT04949854 — N/A

B.D Accucath 5.71 cm 20 Gauge ultralong intravenous catheter 2023 Treatment Timeline for Medical Study. Trial Name: NCT04949854 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the current participant count of this clinical trial?

"Affirmative. Clinicaltrials.gov has data that shows the recruitment for this medical trial, which was first posted on December 1st 2023, is still ongoing. A total of 370 patients are expected to be enrolled from a single clinical site."

Answered by AI

Is the trial currently open for enrollment?

"Affirmative. Evidenced by the information posted on clinicaltrials.gov, this medical trial is still recruiting patients who meet its criteria; it was first published in December 1st 2023 and most recent modified in October 28th 2022. Currently, 370 individuals are needed from one clinic site."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Evaluating the Role of the Guidewire in Peripheral Intravenous Access

Amit Bahl 2023. "Evaluating the Role of the Guidewire in Peripheral Intravenous Access". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04949854.